Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
304.49 6.24   2.09%3002.7M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 8/27/2015

Latest News Headlines for Biogen Inc

Biogen Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

DALLAS--(BUSINESS WIRE)--August 26, 2015-- Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Biogen Inc. ("Biogen") (NasdaqGS: BIIB) and several officers and directors for acts taken during the period of January 29, 2015 to July 23, 2015 (the "Class Period").

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB NEW YORK, NY--(Marketwired - Aug 20, 2015) - The following statement is being issued by Levi & Korsinsky, LLP:

AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed

AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed GAINESVILLE, Fla., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that its collaboration with Biogen (Nasdaq:BIIB), first announced on July 2, 2015 is effective, and Biogen's equity investment in AGTC has closed, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the satisfaction of other customary closing conditions.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

-10.30%
BIIB
Biogen Inc
-7.99%
Johnson & Johnson
Pfizer Inc.
6.77%
-3.24%
Merck & Co., Inc.
-1.42%
AbbVie Inc
BIIB
Biogen Inc
0.00%
Johnson & Johnson
3.12%
Pfizer Inc.
3.37%
Merck & Co., Inc.
3.28%
AbbVie Inc
3.16%
BIIB
Biogen Inc
2.09%
Johnson & Johnson
1.17%
Pfizer Inc.
2.56%
Merck & Co., Inc.
0.97%
AbbVie Inc
2.17%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open301.37
Previous Close304.49
Day High308.50
Day Low299.36
52 Week High3/20/2015 | 480.18
52 Week Low8/24/2015 | 265.00
% Off 52 Week High-36.59%
% Off 52 Week Low14.90%
Beta (5 Yr)0.9
Volatility Avg8/27/2015 | 40.77
10-Day Avg. Volume2,748,917
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2015 | 14.78
P/E Ratio6/30/2015 | 20.6
Market CapLarge Cap | 71.6B
Shares Outstanding235.17M
Float234.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.68M
Short Ratio1.0
Short % of Float1.14%
As of 8/15/2015